Insmed Inc.

23.73+0.0600+0.25%Vol 1.39M1Y Perf -36.95%
Jan 14th, 2022 16:00 DELAYED
BID21.25 ASK23.60
Open23.28 Previous Close23.67
Pre-Market- After-Market23.60
 - -  -0.13 -0.55%
Target Price
52.44 
Analyst Rating
Strong Buy 1.06
Potential %
120.99 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-82/-85/-87 
Value Ranking
★+     44.81
Insiders Value % 3/6/12 mo.
-76/-88/-92 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-77/-89/-92 
Income Ranking
 —    -
Price Range Ratio 52W %
7.38 
Earnings Rating
Neutral
Market Cap2.81B 
Earnings Date
24th Feb 2022
Alpha0.01 Standard Deviation0.27
Beta2.17 

Today's Price Range

22.5423.76

52W Range

22.0045.44

5 Year PE Ratio Range

-4.40-7.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.84%
1 Month
-15.34%
3 Months
-10.42%
6 Months
-13.68%
1 Year
-36.95%
3 Years
1.63%
5 Years
54.09%
10 Years
581.90%

TickerPriceChg.Chg.%
INSM23.730.06000.25
AAPL173.070.88000.51
GOOG2 795.7313.11000.47
MSFT310.205.40001.77
XOM71.871.24001.76
WFC58.062.06003.68
JNJ167.84-0.9200-0.55
FB331.905.42001.66
GE103.160.70000.68
JPM157.89-10.3400-6.15
Financial StrengthValueIndustryS&P 500US Markets
7.70
8.50
0.54
1.19
-11.20
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
76.00
-224.50
-216.20
-
-
RevenueValueIndustryS&P 500US Markets
132.34M
1.12
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2021-0.83-0.96-15.66
Q02 2021-0.85-0.94-10.59
Q01 2021-0.91-0.892.20
Q04 2020-0.67-1.00-49.25
Q03 2020-0.59-0.63-6.78
Q02 2020-0.58-0.64-10.34
Q01 2020-0.67-0.74-10.45
Q04 2019-0.58-0.59-1.72
Earnings Per EndEstimateRevision %Trend
12/2021 QR-0.893.26Positive
12/2021 FY-3.77-5.90Negative
3/2022 QR-0.790.00-
12/2022 FY-3.40-15.65Negative
Next Report Date24th Feb 2022
Estimated EPS Next Report-0.89
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume1.39M
Shares Outstanding118.37M
Shares Float94.73M
Trades Count10.48K
Dollar Volume35.88M
Avg. Volume712.90K
Avg. Weekly Volume821.32K
Avg. Monthly Volume668.00K
Avg. Quarterly Volume753.24K

Insmed Inc. (NASDAQ: INSM) stock closed at 23.73 per share at the end of the most recent trading day (a 0.25% change compared to the prior day closing price) with a volume of 1.39M shares and market capitalization of 2.81B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 521 people. Insmed Inc. CEO is William Lewis.

The one-year performance of Insmed Inc. stock is -36.95%, while year-to-date (YTD) performance is -12.89%. INSM stock has a five-year performance of 54.09%. Its 52-week range is between 22 and 45.44, which gives INSM stock a 52-week price range ratio of 7.38%

Insmed Inc. currently has a PE ratio of -6.60, a price-to-book (PB) ratio of 6.04, a price-to-sale (PS) ratio of 22.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -39.58%, a ROC of -41.77% and a ROE of -98.89%. The company’s profit margin is -%, its EBITDA margin is -216.20%, and its revenue ttm is $132.34 Million , which makes it $1.12 revenue per share.

Of the last four earnings reports from Insmed Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Insmed Inc.’s next earnings report date is 24th Feb 2022.

The consensus rating of Wall Street analysts for Insmed Inc. is Strong Buy (1.06), with a target price of $52.44, which is +120.99% compared to the current price. The earnings rating for Insmed Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Insmed Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Insmed Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.75, ATR14 : 1.37, CCI20 : -164.53, Chaikin Money Flow : 0.12, MACD : -1.08, Money Flow Index : 18.14, ROC : -12.82, RSI : 31.83, STOCH (14,3) : 19.19, STOCH RSI : 0.17, UO : 47.63, Williams %R : -80.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Insmed Inc. in the last 12-months were: Christine A. Pellizzari (Option Excercise at a value of $706 878), Christine A. Pellizzari (Sold 65 150 shares of value $2 803 324 ), David R Brennan (Buy at a value of $301 500), John Soriano (Option Excercise at a value of $1 980 116), John Soriano (Sold 86 478 shares of value $3 271 468 ), Martina Flammer (Sold 2 918 shares of value $76 828 ), Michael Smith (Sold 1 543 shares of value $40 962 ), Roger Adsett (Sold 6 044 shares of value $160 355 ), S. Nicole Schaeffer (Option Excercise at a value of $855 327), S. Nicole Schaeffer (Sold 65 040 shares of value $1 953 988 ), Sara Bonstein (Sold 1 154 shares of value $28 977 ), Steinar J. Engelsen (Buy at a value of $529 042), William Lewis (Option Excercise at a value of $2 336 054), William Lewis (Sold 405 178 shares of value $12 016 324 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
8 (88.89 %)
7 (87.50 %)
Moderate Buy
1 (12.50 %)
1 (11.11 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.06
Strong Buy
1.06
Strong Buy
1.06

Insmed Inc.

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

CEO: William Lewis

Telephone: +1 908 977-9900

Address: 700 US Highway 202/206, Bridgewater 08807, NJ, US

Number of employees: 521

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

News

Stocktwits